The Medtronic COVID-19 Care Evaluation and Monitoring Solution provides in-home evaluation, remote monitoring, and care escalation support.
On April 29, 2020, Daniel O’Day, Chairman & CEO, Gilead Sciences shared an Open Letter following the official press release containing data on Remdesivir and COVID-19.
“The results from the global, placebo-controlled trial run by the National Institute of Allergy and Infectious Diseases (NIAID) are positive. They show that patients with COVID-19 who received remdesivir recovered faster than similar patients who received placebo” O’Day writes. “There is still more work to do and remdesivir has not been approved, but all of us at Gilead are humbled by what these promising results might mean for patients. After years of research and hard work on remdesivir, there is relief and gratitude among our teams today that their efforts have been so worthwhile.”
Study Demonstrates Similar Efficacy with 5- and 10-Day Dosing Durations of RemdesivirContinue reading
PHOENIX — Governor Doug Ducey today announced an extension of physical distancing measures while laying out a step-by-step approach to continue reenergizing Arizona’s economy. The Governor today issued an Executive Order extending Arizona’s Stay Home, Stay Healthy, Stay Connected Order until May 15, 2020.
The order also continues Arizona’s gradual economic reopening, allowing retail businesses to begin partial operations starting next week. Under the order, retail businesses currently not operating can begin curbside pick-up on Monday, May 4, followed by expanded in-person operations on Friday, May 8 as long as they implement social distancing and sanitation measures established by the United States Department of Labor or the Arizona Department of Health Services.Continue reading
Recommendations provided for sponsors and eCOA providers to facilitate the continued collection of PRO data in clinical trials.Continue reading
- NIH mobilizes national innovation initiative for COVID-19 diagnostics
- Initiative aims to speed delivery of accurate, easy-to-use, scalable tests to all Americans.
- With a $1.5 billion investment from federal stimulus funding, the newly launched Rapid Acceleration of Diagnostics (RADx) initiative will infuse funding into early innovative technologies to speed development of rapid and widely accessible COVID-19 testing
- NIH is urging all scientists and inventors with a rapid testing technology to compete in a national COVID-19 testing challenge for a share of up to $500 million over all phases of development.
TEMPE, Ariz. (April 24, 2020) – Sonora Quest Laboratories, the market share leader in diagnostic laboratory testing in Arizona, announced today that it will ramp up its fight against COVID-19 and offer antibody testing for coronavirus (COVID-19) using blood specimens. With this new offering, Sonora Quest now provides healthcare providers in Arizona access to a COVID-19 antibody test as well as the molecular diagnostic testing that has been offered since mid-March.Continue reading
Banner Research provides Donation Coordinators to assist potential donors
PHOENIX (April 24, 2020) – With the need for “convalescent plasma” to treat critically ill COVID-19 patients ramping up as cases rise, Banner Research is providing donation coordinators in metro Phoenix, Tucson and Northern Colorado to help recovered COVID-19 patients get through the plasma donation process. The donation coordinators are equipped to assess qualifying criteria for potential donors, answer questions and explain how the donation process works.Continue reading